1. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481-486
2. Narayan KMV, Boyle JP, Thompson TJ, Gregg EW, Williamson DF. Effect of BMI on lifetime risk of diabetes in the US. Diabs Care 2007; 30: 1562-1566
3. SIGN Management of Diabetes. 2010 No 116
http://www.sign.ac.uk/pdf/sign116.pdf
4. SIGN Management of obesity 2010. A national clinical guideline No 115
http://www.sign.ac.uk/pdf/sign115.pdf
5. International Diabetes Federation. Global guidelines for type 2 Diabetes 2005
http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf
6. Home P, Mant J, Diaz J, Turner C on behalf of the Guideline Development Group. Management of type 2 diabetes: updated NICE guidance. BMJ 2008; 336: 1306-1308
7. Blades M & Morgan J. Audit of referrals for dietary advice from the diabetes clinic at Bedford Hospital. Pract Diabs Int 1996; 13: 184-185
8. Grave RD, Calugi S, Magri F, Cuzzolaro M, Dall’Aglio E, Lucchin L et al. Weight loss expectations in obese patients seeking treatment at medical centers. Obes Res 2004; 12: 2005-2012
9. Foster GD, Wadden TA, Vogt RA, Brewer G. What is a reasonable weight loss? Patients’ expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 1997; 65: 79-85
10. Apfelbaum M, Bostasarron J. Energy metabolism in the obese on a restricted diet. Presse Med l969; 52: 1941-1943
11. Bray GA. Effect of caloric restriction on energy expenditure in obese patients. Lancet 1969; 2: 397-398
12. Pories WJ, MacDonald KG Jr, Flickinger EG, Dohm GL, Sinha MK, Barakat HA et al. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg 1992; 215:633-642
13. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122(3): 248-256
14. Sjostrom L, Lindross AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B et al. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. NEJM 2004; 351: 2683-2693
15. Dixon JB, O’Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomised controlled trial. JAMA 2008; 299: 316-323
16. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding MP, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147: 1749-1753
17. Klein S. Outcome success in obesity. Obes Res 2001; 4: 354S-358S
18. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003; 22: 331-339
19. Lean MEJ, Powrie JK, Anderson AS, Garthwaite PH. Obesity, weight loss and prognosis in type 2 diabetes. Diab Med 1990; 7: 228-233
20. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diab Care 2000; 23:1499-1504
21. Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA. Mortality in people with type 2 diabetes in the UK. Diabet Med 2006; 23: 516-521
22. Sjostrom CD, Peltonen M, Wedel H, Sjostrom L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000; 36: 20-25
23. NICE – Type 2 diabetes 2008
http://www.nice.org.uk/nicemedia/live/11983/40803/40803.pdf
24. UKPDS 38. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998; 317: 703-713
25. Echouffo-Tcheugui JB, Sargeant LA, Prevost AT, Williams KM, Barling RS, Butler R et al. How much might cardiovascular disease risk be reduced by intensive therapy in people with screen-detected diabetes? Diab Med 2008; 25: 1433-1439
26. Emslie-Smith A, Dowall J, Morris A (2003). The problem of polypharmacy in type 2 diabetes. B J Diab & Vas Dis 3:54
27. Frigg A, Peterli R, Peters T, Ackermann C, Tondelli P. Reduction in co-morbidities 4 years after laparoscopic adjustable gastric banding. Obes Surg 2004; 14: 216-223
28. Erlinger S. Gallstones in obesity and weight loss. Eur J Gastroenterol 2000; 12: 1347-1352
29. NICE: Obesity. Guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. 2006
http://www.nice.org.uk/nicemedia/pdf/CG43NICEGuidance.pdf
30. The Counterweight Project Team. Evaluation of the Counterweight Programme for obesity management in primary care: a starting point for continuous improvement. Brit J Gen Pract 2008; 58: 548-554
31. The Counterweight Project Team. Long-term cost-effectiveness of weight management in primary care. IJCP 2010; 64: 775-783
32. Rissanen A, Lean MEJ, Rossner S, Segal KR, Sjostrom L. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. IJO 2003; 27: 103-109
33.
34. Lean MEJ & Finer N. Management: Part II – Drugs. ABC of Obesity. BMJ 2006; 333: 794-797
35. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial Obesity Reduction and Maintenance. Lancet 2000; 356: 2119-2125
36. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK et al. Randomised trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353: 2111-2120
37. Astrup A, Rossner S, Van Gaal L et al on behalf of the NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-1616
38. Lean MEJ, Astrup A, Al Hakim et al. Sustained weight loss and acceptable tolerability with the GLP-1 anologue liraglutide in obese non-diabetic adults: a 2-year randomized trial. Obesity 2010; (abstract 484-P) (in press)
39. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481
40. Franz MJ, VanWormer JJ, Crain AL, Boucher JL, Histon T, Caplan W et al. Weight-loss outcomes : a systematic review and meta-analysis of weight loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 2007; 107: 1755-1767
41. Riecke BF, Christensen R, Christensen P, Leeds AR, Boesen M, Lohmander LS et al. Comparing two low-energy diets for the treatment of knee osteoarthritis symptoms in obese patients: a pragmatic randomized clinical trial. Osteoarth Cart 2010; 18(6): 746-754
42. Finer N, Finer S, Naoumova RP. Drug therapy after very-low-calorie diets. AJCN 1992; 56:195S-198S
43. Andersen T, Astrup A, Quaade F. Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial. IJO 1992; 16: 35-40
44. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very low-calorie diet: a randomised blinded trial of the efficacy and tolerability of sibutramine. Amer J Med 1999; 106:179-184
45. Mathus-Vliegen EM for the Balance Study Group. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study. EJCN 2005; 59:S31-S38
46. Richelsen B, Tonstad S, Rossner S, Toubro S, Niskanen L, Madsbad S et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients. Diab Care 2007; 30: 27-32
47. Torgerson JS, Agren L, Sjostrom L. Effects on body weight of strict or liberal adherence to an initial period of VLCD treatment. A randomised, one-year clinical trial of obese subjects. IJO 1999; 23: 190-197
48. Lin WY, Wu CH, Chu NF, Chang CJ. Efficacy and safety of very-low-calorie diet in Taiwanese: a multicenter randomized, controlled trial. Nutrition 2009; 25: 1129-1136
49. Wadden TA, West DS, Neiberg RH, Wing RR, Ryan DH, Johnson KC et al. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity 2009; 17(4):713-722
50. Christensen R, Leeds AR, Lohmander S, Christensen P, Riecke BF, Sorensen TJ et al. Efficacy of dieting or exercise vs control in obese osteoarthritis patients after a clinically significant weight loss: a pragmatic randomized controlled trial. Obes Rev 2010; 11(S1):248 (T3:PO.83)